Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $31.51 in the last session, up 8.17% from day before closing price of $29.13. In other words, the price has increased by $8.17 from its previous closing price. On the day, 2.76 million shares were traded. ARWR stock price reached its highest trading level at $31.62 during the session, while it also had its lowest trading level at $29.82.
Ratios:
We take a closer look at ARWR’s different ratios to gain a better understanding of. The Stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.87 and its Current Ratio is at 4.87. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The Stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned. The Stock a target price of $31.
On December 04, 2023, BofA Securities started tracking. The Stock assigning a Buy rating and target price of $29. On September 19, 2023, Citigroup started tracking. The Stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 12 ’25 when Hamilton James C sold 15,000 shares for $30.00 per share. The transaction valued at 450,000 led to the insider holds 232,122 shares of the business.
Hamilton James C bought 15,000 shares of ARWR for $449,970 on Sep 12 ’25. On Sep 02 ’25, another insider, Hamilton James C, who serves as the Chief Medical Officer of the company, sold 15,000 shares for $25.00 each. As a result, the insider received 375,000 and left with 247,122 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 4356495360 and an Enterprise Value of 4169102336. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 7.60 while its Price-to-Book (P/B) ratio in mrq is 8.33. Its current Enterprise Value per Revenue stands at 7.276 whereas that against EBITDA is -48.821.
Stock Price History:
The Beta on a monthly basis for ARWR is 1.06, which has changed by 0.5149039 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $31.13, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of. The Stock is 51.04%, while the 200-Day Moving Average is calculated to be 74.70%.
Shares Statistics:
According to the various share statistics, ARWR traded on average about 2.32M shares per day over the past 3-months and 2560710 shares per day over the past 10 days. A total of 138.14M shares are outstanding, with a floating share count of 128.33M. Insiders hold about 7.18% of the company’s shares, while institutions hold 74.94% stake in the company. Shares short for ARWR as of 1756425600 were 12729088 with a Short Ratio of 5.48, compared to 1753920000 on 12937337. Therefore, it implies a Short% of Shares Outstanding of 12729088 and a Short% of Float of 11.88.
Earnings Estimates
The market rating of Arrowhead Pharmaceuticals Inc (ARWR) is currently shaped by the ongoing analysis conducted by 12.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.34, with high estimates of $2.0 and low estimates of -$1.08.
Analysts are recommending an EPS of between $0.82 and -$1.06 for the fiscal current year, implying an average EPS of -$0.22. EPS for the following year is -$2.88, with 12.0 analysts recommending between -$0.85 and -$4.55.
Revenue Estimates
For the next quarter, 13 analysts are estimating revenue of $244.26M. There is a high estimate of $468.84M for the next quarter, whereas the lowest estimate is $22.8M.
A total of 15 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $923M, while the lowest revenue estimate was $573M, resulting in an average revenue estimate of $735.77M. In the same quarter a year ago, actual revenue was $3.55MBased on 15 analysts’ estimates, the company’s revenue will be $382.73M in the next fiscal year. The high estimate is $646.8M and the low estimate is $94.3M.
